Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURVEYOR-II: Glecaprevir/Pibrentasvir in Chronic HCV GT2-6
NCT02243293Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2014
- Primary completion
- Oct 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Sep 2014; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02243293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243293.